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A controlled trial of nandrolone decanoate in the treatment of
nremic anemia. Thirty-seven male dialysis patients, from three
university hospital centers known to have adequate iron, B12, and
folate stores, were entered into a controlled trial to study the
effects of nandrolone decanoate (200 mg i.m. weekly) on their
anemia. An initial six-month stabilization period was followed by a
randomized 12-month study, with crossover between treatment
and control groups occurring at six months. Patients received
parenteral iron therapy plus oral folate throughout the trial. All
serious illnesses or major blood losses excluded the patients from
analysis. The 24 patients with remnant kidneys showed an increase
in hemoglobin and hematocrit of 24% by the end of six months of
treatment (P <0.005), with a corresponding decrement during the
six months of control, but the five anephric patients showed no
statistically signfieant change compared to those patients whose
kidneys were in place during the study. Complications of treat-
ment were minimal, with injection site hematoma the only signifi-
cant local effect and a rise in triglyceride the only significant
systemic disturbance. Despite the improvement in anemia, the
disadvantages, including the high cost of treatment, the apparent
plateauing of benefits by five months, the minimal subjective
improvement in life style, the risk of i.m. injection, plus the long
term effects of increased lipids, should limit this therapy to
patients with remnant kidneys who have severe symptomatic
anemia or frequent transfusion requirements.
Essal contrôlé dn décanoate de nandrolone dans le traitement de
l'anémie au cours de l'urémie. Trente sept malades du sexe mascu-
un soumis a l'hémodialyse ehronique, dans trois centres hospital-
iers universitaires, dont les reserves de fer, de B12 et de folate
étaient adéquates, ont été inclus dans une étude eontrôlée afin
d'évaluer les effets du décanoate de nandrolone, a raison de 200
mg i.m. par semaine, sur leur anémie. Une période initiate de
stabilisation de six mois a été suivie d'une étude randomisée de 12
mois avee passage a six mois d'un groupe a l'autre, contrOle ou
traité. Les matades ont regu du fer par voie parentérale et du folate
per os pendant tout l'essai. Une maladie sévére on une perle de
sang importante a fait exelure les malades de l'étude. Les 24
malades ayant des reins restants ont eu une augmentation de
t'hémoglobine et de l'hématocrite de 24% a la fin des six mois de
traitement (P < 0,005) avec une diminution eorrespandante pen-
dant les six mois de la période contrôle. Les cinq malades anéph-
riques, par contre, n'ont pas eu de modification statistiquement
signifleative, par comparaison avec les malades dont les reins
étaient en place pendant l'étude. Les complications du traitement
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ont été minimes. Le seul effet local de quelque importance a été
des hématomes au lieu d'injection et le seul effet systémique une
augmentation des triglycerides. En dépit de l'amelioration de
l'anémie ee traitement doit étre réservé aux malades qui ont des
reins restants et dont t'anémie est sCvére et symptamatique ou qui
ant besoin de transfusions frequentes. Les inconvCnients, en effet,
sont le coOt élevC du traitement, le risque d'infection intra-muscu-
laire, l'amélioration subjective minime du mode de vie, les effets
au long cours de l'augmentation des lipides.
Anemia is an inevitable consequence of chronic
renal failure and is only partially responsive to artifi-
cial kidney treatment [1, 21. The cause of the anemia
is multifactorial, but decreased erythropoietin pro-
duction by the diseased kidney is the most important
factor in the persistence of the anemia once the
patient is stable on dialysis and blood loss is mini-
mized. The observation that the anemia is more
severe in nephrectomized patients helps confirm that
this hormonal defect is a prime factor [3, 4]. Other
contributing factors include folate deficiency [5, 61
and iron deficiency. The latter may develop second-
ary to defective intestinal absorption [71, blood loss
from routine tests, dialyzer leaks, and/or entrapment
in extracorporeal circuits [81. Hemolysis [9] and loss
of red cells into the skin secondary to platelet abnor-
malities [101 may also contribute to iron depletion.
The hemolytic component of the anemia and the
abnormality of platelet function do return toward
normal with adequate dialysis treatment [9, 11].
Blood transfusions have been used in many cen-
ters to treat symptomatic anemia, but the expense,
the occurrences of hepatitis [12], hemosiderosis, as
well as the possibility of sensitizing patients to HLA
antigens, and hence increasing the difficulty of
obtaining a suitable renal allograft [13], caution the
physician against this approach. Recently, andro-
gens have been employed in the treatment of uremic
anemia. These agents have been successfully used
for many years in a variety of hypoplastic anemias
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14, 15]. They act by both increasing plasma erythro-
poietin activity [16] and by increasing the pool size
of erythropoietin responsive cells [17, 18].
This prospective controlled trial in uremic patients
using nandrolone decanoate (Decadurabolin®, Orga-
non Canada Ltd., Ontario) was initiated because
early studies with androgens were encouraging, but
the numbers were small [19], the trials were uncon-
trolled [20], the treatment periods were short [211 or
hard to assess because of intrastudy transfusions [3].
Methods
Thirty-seven male patients, aged 25 to 66 yrs., who
had been stable on chronic dialysis for at least six
months (6 to 63 months) were selected for the study.
Twenty-four patients were on home hemodialysis,
twelve were on center hemodialysis, and one was on
home peritoneal dialysis. The primary renal disease
was glomerulonephritis in 24, interstitial nephritis in
five, polycystic in two, hypertensive nephrosclerosis
in one, hereditary nephritis in one, and undefined in
four patients. Five patients were anephric at the time
of the study (hereditary nephritis in one, polycystic-
tis in one, and glomerulonephritis in three). After
informed consent was obtained, a bone marrow aspi-
ration was done on all patients during the initial six-
month stabilization period to assess erythropoiesis
and iron stores [22]. Parenteral iron dextran (Imfer-
on®), 1500 mg initially and then every six months, or
200 mg monthly, was given to all patients unless their
initial bone marrow sample showed an excess of
stainable iron. Seven patients who had absent iron
stores on initial assessment were given an extra dose
of iron i.v. and showed adequate stores on repeat
marrow sampling prior to starting the trial. To check
that this was sufficient iron replacement and that
adequate iron was available for hematopoiesis during
the study, bone marrow aspiration was repeated in
the first ten patients to complete the study. Drugs
given to all patients included aluminum hydroxide
for phosphate control, and a daily oral supplement
containing 150 mg of elemental iron, and 2.5 mg of
folic acid. Other drugs included oral anticoagulants
in eight patients and antihypertensive medication in
three patients. No blood transfusions were given to
any patient for at least six months prior to initiation
of the protocol, and none had previously received
androgen therapy. Dietary protein was maintained at
1 g!kg of body wt during the study. All patients had a
monthly general assessment throughout the observa-
tion period and trial period to ensure no extra source
of blood loss (e.g., peptic ulcer), and that good tech-
nique regarding cannulation and blood return was
being observed. Hemoglobin, hematocrit, and reticu-
locyte count were measured monthly before dialysis
on the same day of the week to help minimize
changes due to fluid volume variation. Serum iron
and iron-binding capacity (Technicon N-62 1111,
Technicon Instrument Corporation, Tarrytown, NY)
[23, 24], vitamin B12 and serum folate levels [25],
cholesterol [26], triglyceride [27], and lipoprotein
electrophoresis [28], bilirubin, alkaline phosphatase,
and serum glutamic pyruvic transarninase (SGOT)
were measured every three months.
The patients were randomly allocated to either
treatment or control group following the stabilization
period, with the treatment group receiving nandro-
lone decanoate (Decadurabolin®), 200 mg i.m. week-
ly for six months, the control patients receiving no
therapy, followed by a crossover and a subsequent
six months of observation. Nandrolone decanoate
injections were given by a renal unit nurse to hospital
dialysis patients and by the spouse, visiting nurse, or
family practitioner to the home dialysis patients. The
drug was dispensed through a central area, and total
dose received by each patient was checked by a
pharmacist.
Paired Student's t test was used in the statistical
analysis.
Results
Twenty-nine of the original 37 patients were ana-
lyzed, with 24 completing the full 12 months and five
others completing at least six months of treatment
plus five months of control. Eighteen patients
received androgens before (groups 1A and 2A) and
11 received androgens after the control period
(groups lB and 2B), as outlined in Table 1. The
reasons for not fully completing the study in 13
patients are outlined in Table 2. Drug-related compli-
cations were uncommon. The only directly related
complication was tremors lasting for several hours
after each injection, which developed in one patient
(patient no. 1). One patient with hypercalcemia
(patient no. 2) had this persist after discontinuing the
medication and was later shown to have hyperpara-
thyroidism. The development of pericarditis, which
developed in one patient (patient no. 3) is not uncom-
mon in the general dialysis population and thus is
unlikely to be directly drug-related. Three patients
developed severe and significant hemorrhage during
therapy, one at the injection site, another retroperito-
neally resulting in nephrectomy, and the third bled
into the vitreous humor of his eye. The last two were
probably not directly related to the drug, as hemato-
logical evaluation, including complete coagulation
screening, was normal at the time of hemorrhage.
Renal transplantation eliminated two other patients
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Table 1. Change in hemoglobin and hematocrit during observation, androgen therapy, and control period in the 29 patients who completed
the full six months of treatment with nandro]one decanoate
Observation period, months And
I
rogen
2
treatme
3
nt pen
4
od, months Con
5 6 1 2
trol pedod, months
Patientno. 1 2 3 4 5 6 3 4 5 6
Group IA
3.9 4.3 5.2 4.0 3.4 4.6 5.5 6.2 6.9 8.7 7.5 7.0 8.5 5.2 6.2 6.0 5.9 5.5
13.9 15.5 17.6 14.5 13.1 14.3 17.4 19.1 21.3 26.0 24.5 22.1 27.7 16.8 19.8 19 19 17
5.1 4.0 3.1 4.3 3.5 5.5 4.7 4.8 6.5 6.5 6.5 6.5 5.9 6.0 5.9 5.5 4.8
19.0 15.6 13.6 17.5 15.4 19.4 19.6 16.3 22.2 21.0 21.8 23.1 21.0 18.9 21.0 19.4 16.6
5.4 — 5.1 5.2 5.0 5.3 5.4 7.1 6.9 5.8 6.5 6.6 6.3 5.0 5.1 4.3 4.4 —
16.3 — 16.1 17.9 17.4 17.6 16.3 20.7 18.9 18.2 20 20.7 19.4 15.7 14.6 13.1 14.0 —
4 4.0 3.7 5.4 4.0 5.3 5.6 4.8 6.5 5.1 6.1 6.0 6.4 6.2 5.9 5.2 6.1 6.9 6.2
14.2 14.0 18.0 15.4 17.5 18.0 5.8 20.9 16.2 20.4 19.3 21.0 19.3 20.9 16.8 19.5 21.0 19.4
4.5 4.5 4.9 4.9 4.8 6.6 5.1 5.7 6.8 7.1 6.4 5.3 5.1 6.6 4.5 5.1 3.7 —
15.0 15.5 14.0 14.8 18.2 20.6 15.1 16.6 17.6 19.5 19.1 15.6 15.9 21.6 13.1 15.2 12.3
6 5.6 6.5 6.1 5.3 5.4 6.0 6.2 5.8 6.8 7.9 8.8 8.4 6.4 6.3 6.1 6.0 5.9 5.8
17.2 19.4 19.9 16.6 16.5 19.3 20.4 17.8 21.4 23.1 27.4 25.2 19.2 20.7 18.0 18.0 18.0 17.0
7 4.6 4.3 4.6 3.7 4.3 3.8 5.3 7.3 8.0 6.2 7.6 7.9 7.7 7.7 7.5 7.0 6.8 6.5
14.7 13.5 14.3 12.4 13.6 11.5 16.3 22.6 24.5 19.2 23.7 26.8 24.4 23.0 23.0 21.0 21.0 20.0
8 7.4 6.6 8.4 9.6 9.8 9.0 8.5 8.8 9.7 9.1 10.3 10.2 10.0 8.3 8.6 8.2 7.9 7.4
23.2 20.6 26.2 31.8 30.5 29.8 26.6 28.7 31.6 29.4 31.5 32.3 30 25.8 26 25 26 23
9 8.1 6.9 6.5 6.7 7.6 6.8 7.4 7.3 8.3 9.1 8.2 8.7 9.3 9.2 9.0 8.6 8.6 8.1
24.7 21.0 20.3 21.6 23.1 20.4 23.4 23.6 25.9 27.9 25.5 27.1 28.9 28 27 24 25 24
10 7.1 6.1 6.6 7.0 6.7 6.5 7.5 8.8 7.5 7.7 6.5 6.3 4.8 6.4 5.7 5.5 6.1 —
23 19 21 22 22 22 24 28 23 24 21 21 II 22 20 18 20 —
II 6.8 6.8 6.2 6.4 6.2 7.5 10.1 9.6 10.1 8.9 10.1 8.5 8.9 7.6 7.6 7.2 7.0 6.9
22 23 19 21 20 23 32 31 32 28 31 27 29 24 23 21 20 21
12 6.5 6.5 6.4 6.4 6.4 6.4 6.6 7.7 7.7 7.9 7.9 7.2 6.0 7.3 7.1 7.1 6.5
20 20 20 20 20 20 21 24 — 24 25 26 24 20 22 23 24 20
13 4.4 — 4.4 4.4 4.8 4.9 5.1 5.8 5.8 5.8 5.8 5.8 4.9 4.3 4.2 3.8 4.0 —
13 — 14 15 14.3 15.4 15.4 17 17 17 17 15.4 14.8 13 13.4 11.8 13 —
14 9.1 6.7 8.0 8.7 6.9 7.1 8.0 9.5 9.3 8.2 9.3 10.1 9.4 9.0 8.7 6.4 6.2 6.2
27 20 25 26 22 23 25 30 29 21 30 33 30 29 27 20 20 20
15 5.4 5.7 5.3 5.5 5.1 6.0 7.1 7.4 7.4 7.0 8.5 10.1 8.8 8.0 7.8 8.2 6.4 —
17 18 16 19 16 19 23 24 24 23 28 33 30 26 25 27 21 —.
Mean Hb 5.9 5.6 5.7 5.7 5.7 6.1 6.5 7.2 7.5 7.5 7.7 7.7 7.4 6.8 6.6 6.4 6.2 6.4
SEM 0.4 0.3 0.4 0.4 0.4 0.3 0.4 0.4 0.4 0.4 0.4 0.4 0.5 0.4 0.4 0.4 0.4 0.3
P value NS —* < <0.0(15 —E---—-—<0.O5
<0.0025
Mean Hct 18.7 18.1 18.3 19.0 18.6 19.6 20.8 22.7 23.2 22.8 24.3 24.6 23.1 21.8 20.5 19.8 19.6 19.8
SEM 1.1 0.8 1.0 1.3 1.2 1.1 1.3 1.3 L4 1.0 1.2 1.4 1.7 1.1 1.2 1.1 1.0 0.8
P value —<0.025 —
—> < <0.0025
'-<0.025
from the study. Several other patients developed received the full six months of Decadurabolin
mild pain at the site of injection, but therapy was treatment.
continued and the symptoms seemed to decrease The monthly hematological values in the 29
with time. Five patients of the study group were patients analyzed are outlined in Table 1. There was
withdrawn at eleven months, two patients because of no significant change in the remnant kidney patients
severe and symptomatic anemia which required (group 1) or the anephric patients (group 2) in either
blood transfusions, two because of transplantation, hemoglobin or hematocrit during the initial six
and one because he developed subacute bacterial months of observation, despite i.v. iron supplement.
endocarditis. All five patients had previously By the end of androgen treatment, however, the
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Table 1 (continued)
Observation period, months Control period, months Androgen treatment penod, months
Patientno. 1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6
1 6.9
23.4
6.8
23.0
6.7 6.7
22.3 22.0
6.8
22.8
7.1
21.3
6.4
20.6
Group lB
6.4 7.4 6.6
21.2 22.8 22.2
7.7
25.2
7.3 7.7 7.4
25.5 22.0 23.2
7.8
25.5
6.5
20.0
6.8
21
7.2
24.4
2 5.9
17.2
5.5
18.0
5.3 5.2
19.8 15.4
5.4
18.1
5.3
18.3
5.6
17.8
5.7 5.5 5.5
18.1 16.0 16.0
5.7
18.1
5.2 5.5 5.5
16.6 18.6 18.0
5.7
19.0
6.1
18.3
6.6
21.0
7.0
22.2
3 7.5
23.9
7.8
23.8
6.0 5.2
21 16.6
5.3
16.3
5.6
17
5.5
17.4
4.5 4.8 5.6
13.9 15.9 17.1
5.0
16
6.0 5.7 6.0
19 17.3 18
7.1
21.9
6.9
21.0
6.9
21
7.2
22
4 6.6
20
7.2
22
7.3 7.1
22 21
7.9
25
8.2
25
7.8
24
7.6 — 7.5
20 — 24
7.7
25
7.9 8.1 8.0
26 25 25
8.2
25
7.2
21
7.6
21
8.6
29
5 6.7
20
8.8
25
6.8 7.4
22 24
7.7
28
7.0
23
8.5
28
9.5 10.5 9.8
30 34 34
8.7
26
8.1 6.5 8.6
24 20 27
7.2
23
9.1
32
10.5
39
10.6
40
6 6.5
20
5.4
18
5.0 6.1
16 20
6.3
19
6.6
21
5.6
21
5.4 5.0 4.9
20 19 18
4.5
16
4.9 6.9 7.3
15 22 24
7.6
26
7.4
24
7.9
25
8.4
28
7 8.3
26
8.3
25
8.9 10.2
29 32
10.0
31
10.0
29
8.6
27
8.3 6.7 8.4
27 22 26
9.3
29
9.0 9.5 10.2
26 28 32
10.3
30
10.1
33
9.2
29
10.2
31
8 6.2
18
6.5
20
7.4 6.1
22 18
6.4
21
7.3
21
6.6
20
6.4 7.6 7.4
19 23 22
7.2
21
6.0 6.4 6.9
19 22 21
7.0
21
—
—
5.8
19
6.1
19
9 7.2
21
7.2
22
7.1 7.0
23 22.8
6.8
19.9
5.6
17.5
7.5
22.2
8.2 8.1 7.8
24.9 23.8 23.2
7.2
22
6.0 6.1 6.8
17 19.1 22.6
7.2
21.6
7.4
22
7.4
23
8.1
22.6
Mean Hb
SEM
Pvalue
Mean Hct
SEM
P value
6.9
0.2
<
21.1
2.9
<
7.1
0.4
21.9
2.7
6.7 6.8
0.4 0.5
NS
21.9 21.3
3.4 4.9
NS
7.0
0.5
22.3
4.8
7.0
0.5
>(
21.5
3.8
>
6.9
0.4
22
3.7
6.9 7.0 7.1
0.5 0.7 0.5
NS
21.6 22.1 22.5
4.9 5.7 5.5
NS
7.0
0.5
22
4.6
6.7 6.9 7.4
0.5 0.4 0.5
>—<0.10-----
<0.005
20.9 19.3 23.4
4.5 4.8 4.4
<0.025
7.6
0.4
7.6
0.5
7.6
0.5
8.2
0.5
23.7
3.3
—
23.9
5.5
24.3
6.2
26.5
6.4
)
E-<0.I5 —
mean increase in both these parameters was very
significant in groups 1A and IB, with the hemoglobin
increasing 1.7 g/100ml and the hematocrit increasing
4.7% (P value was significant by three months in
group 1A, <0.05, and highly significant by six
months in both groups IA, P <0.0025, and 1B, P <
0.005). A corresponding decrement was noted in
both values during the control period in those
patients receiving the androgen in the first phase
(group 1A). The time-response curve was similar
whether the patients received androgens before or
after the control period. The increase in hemoglobin
and hematocrit with treatment was equal in both the
home dialysis and hospital dialysis patients. When
analyzed independently, the five anephric patients
(group 2), with treatment, showed a mean increase in
hematocrit of 1.2% and in hemoglobin of 0.4 g/l00
ml, but this was not significantly different from their
control values.
Liver function tests remained stable throughout
the trial. Masculinizing effects were minimal, but so
was subjective improvement in energy, with only
those whose hemoglobin rose by> 2 g (8/29) noting
any significant change. There was no improvement in
libido with androgen treatment. Serum folate was not
influenced by androgen therapy and was high
throughout all phases of the study. The serum iron
and total iron binding capacity was not significantly
different before, compared to after, androgen thera-
py, 67 8 and 298 17 tg/dl (mean SEM) vs. 69
7 and 306 19 j.g/dl. Lipid assessment before and
after treatment showed an unchanged cholesterol
value, 191 11 vs. 194 10 mg/100 ml, but a
significant rise in triglyceride concentrations was
shown, from 185 20 to 238 70 mg/l00 ml, using
paired t test, P < 0.10 (Table 3). The average dry
weight of the patients with androgen therapy
increased 1.6 kg, and this increase in muscle mass
was reflected by a change in predialysis creatinine
values from 12.4 1 to 13.7 1.4 mg/100 ml.
Discussion
Many previous articles have attempted to eluci-
date the role of androgens in the treatment of dialysis
anemia. Early studies using testosterone seemed to
show a significant increase in hematocrit in a high
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Table 1 (continued)
Observation period, months Androgen treatment pen od, months Control period, months
Patientno. I 2 3 4 5 6 I 2 3 4 5 6 1 2 3 4 5 6
1 5.3 5.2 5.2 5.3 6.5 5.9
Group 2A
6.0 4.6 4.0 4.8 4.5 6.0 6.0 6.1 5.4 6.0 4.9 4.6
15 15 16 17 18 18 19 14 13 15 13 16 16 18 16 18 17 14
2 4.3 5.9 3.7 4.0 3.8 4.1 3.8 3.9 5.2 6.2 6.1 5.4 5.9 5.8 5.6 5.2 5.2 5.0
13 18 12 15 12 13 13 13 16 19 18 17 17 17 17 17 16 15
3 4.2 4.1 5.6 5.1 5.6 5.4 5.9 4.6 5.1 5.1 5.1 5.7 5.3 6.0 6.0 6.3 5.5 5.8
14 13 16 15 17 16 16 14 16 16 15 18 18 18 18 19 17 16
Mean Hb 4.6 5.1 4.8 4.8 5.3 5.1 5.2 4.4 4.8 5.4 5.2 5.7 5.7 6.0 5.7 5.8 5.2 5.1
SEM 0.4 0.5 0.6 0.4 0.8 0.5 0.7 0.2 0.4 0.4 0.5 0.2 0.2 0.1 0.2 0.3 0.2 0.4
P value < NS >< NS >< NS >
Mean 1-Jet 14.0 15.3 14.7 15.7 15.7 15.7 16.0 13.7 15.0 16.7 15.3 17.0 17.0 17.7 17.0 18.0 16.7 15.0
SEM 0.6 1.5 1.3 0.7 1.9 1.5 1.7 0.3 1.0 1.2 1.5 0.6 0.6 0.3 0.6 0.6 0.3 0.6
P value < NS < NS >< NS )
1 5.4 5.4 5.3 4.5 3.8 4.2
Group 2B
4.0 4.8 4.7 4.8 4.9 4.8 5.0 4.7 4.6 4.7 4.7 4.7
21 21 16 13 II IS 15 16 16 17 16 17 18 16 16 17 17 17
2 4.5 4.1 4.4 3.9 4.0 4.2 4.6 4.2 5.1 4.6 4.2 3.9 4.7 4.2 4.2 3.6 4.2 4.3
15 13 13 12 13 14 15 14 17 15 14 13 IS 15 13 13 13 14
Mean Hb 5.0 4.8 4.9 4.2 3.9 4.2 4.3 4.5 4.9 4.7 4.6 4.4 4.9 4.5 4.4 4.2 4.5 4.5
SEM 0.5 0.7 0.5 0.3 0.1 0.0 0.3 0.3 0.2 0.1 0.4 0.5 0.1 0.3 0.2 0.6 0.3 0.2
Pvalue < NS >< NS >< NS >
Mean Hct 18.0 17.0 14.5 12.5 12.0 14.5 15.0 15.0 16.5 16.0 15.0 15.0 16.5 l5.5 14.5 15.0 15.0 15.5
SEM 3.0 4.0 1.5 0.5 1.0 0.5 0.0 1.0 0.5 1.0 1.0 2.0 1.5 0.5 1.5 2.0 2.0 1.5
Pvalue < NS >< NS >< NS >
percentage of patients treated, but these trials were
limited in the number of patients studied [19], were
treated immediately after starting dialysis [20], when
frequently improvement is seen in all patients
because of improvement in red cell survival [11], or
were uncontrolled or lacked adequate assurance that
precursor substances were available for hemoglobin
synthesis [211. More recently, other authors have
been unable to duplicate these early dramatic results
[29]. These variable findings regarding effectiveness
plus the high incidence of cholestatic jaundice, hirsu-
tism, and priapism [20, 21, 30] have led others to
study the effects of oral androgens. Davis et al [31] in
a well controlled study showed no significant change
in hemoglobin or hematocrit with the oral agent,
oxymetholone; but fluoxymesterone, another 17-
aipha-alkalated oral androgen, was shown to be
effective [32, 33]. These latter studies, however,
were uncontrolled, and transfusions were not discon-
tinued during the trial.
This spectrum of results on the effectiveness of
both i.m. and oral agents, together with the previous
observation by Gorsheim, Murphy, aiid Gardner,
[341 that nandrolone decanoate (on a mole to mole
basis) was the most potent androgen, coupled with
Table 2. Reasons for not completing study on patients undergoing
nandrolone decanoate therapy for uremic anemia
Patient Reasons for failure to complete Time in
no. study period
1
Daring androgen therapy
Allergic reaction I wk.
2 Hypercalcemia 4 mos.
3 Pericarditis I mo.
4 Injection site hematoma 3 mos.
S Retroperitoneal hemorrhage 3 mos.
6 Vitreous hemorrhage 4 mos.
7 Renal transplantation 3 wks.
8 Renal transplantation 2 mos.
9
During control period
Transfused 5 mos.
10 Transfused 5 mos.
11 Renal transplantation 5 mos.
12 Renal transplantation 5 mos.
13 Subacute bacterial endocarditis 5 mos.
its proven efficacy in the treatment of patients with
aplastic anemia [35] and its low incidence of hepato-
toxicity and virilizing effects [361, prompted us to
use this medication in a controlled study. We showed
a very significant increase in hemoglobin and hema-
tocrit (P < 0.005) with treatment, but the increase
appeared maximum by five months, and the majority
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Patient no.
Before treatm
mgIIOO ml
ent After treatment
,ng/JOO ml
1 97 167
2 212 260
3 210 312
4 132 165
5 165 185
6 108 152
7 150 190
8 232 328
9 185 —
10 83 97
11 — 240
12 505 668
13 149 136
14 113 130
15 300 340
16 474 490
17 100 104
18 60 328
19 186 138
20 60 110
21 172 240
22 195 —
23 199 199
24 232 260
25 200 242
26 59 64
27 207 227
28 210 250
29 185 240
SEM 185±20 238±70
Pvalue <0.10
of patients did not have a noticeable change in life
style with the drug. Williams, Stein, and Ferris [37]
have recently shown that this dosage significantly
increased hemoglobin when compared to a control
group, even though the treated group was small (nine
patients), the treatment period was short (13 weeks),
and there was no crossover in their design. Hendler
et al [38], in a well designed study using a lower dose
of the same agent (100mg weekly, i.m.) had a similar
improvement, but variable effects were noted on ane-
phric patients, and transfusions were continued dur-
ing both the treatment and control periods, compli-
cating the analysis. We have attempted to eliminate
these sources of error in our study and have shown in
a much larger group of patients that there is a signifi-
cant increase in both hemoglobin and hematocrit
with the drug in patients with remnant kidneys. In an
attempt to minimize hematocrit changes because of
fluid weight gain between dialysis, the hematological
parameters were measured on the same day of the
week each month and clinical assessment was done
by one of the principal investigators in an attempt to
assess that the volume status was approximately the
same each time. Hemodilution may influence these
measurements, but this would weigh in favor of
reducing the hematocrit with treatment, since andro-
gens may cause fluid retention. The fact that the
anephric patients did not vary in these parameters
during treatment helps support our contention that
the changes in these values in the remnant kidney
group is real. The careful study of Hendler et al [38]
showed that significant hematocrit changes lagged
behind red blood cell mass changes, again supporting
our conclusion that the hemoglobin and hematocrit
changes were a real and valid test of the effects of the
drug.
Unlike Hendler et al who noted a better response
in the hospital population vs. the home patients, we
observed an equal effect in these groups. This dis-
crepancy may have been due to decreased compli-
ance in the home patients. We ensured regular usage
by utilizing medical or paramedical personnel in the
unreliable home patients and by checking that the
amount dispensed by the pharmacy equalled the
expected total.
Literature on the effects of androgens on anephric
patients is conflicting. Shaldon et al [30] showed an
improvement in 5/5 anephric patients with testoster-
one therapy; Doane, Fried, and Swartz [3] showed
an improvement in 4/7 patients with nandrolone
decanoate therapy; and Eschbach and Adamson [32]
showed an improvement in 2/3 patients with fluoxy-
mesterone therapy; whereas Fried et al [4] found
that 0/5 patients responded to testosterone treat-
ment. All of the studies showing a response were
uncontrolled, and/or transfusions were given in both
the treatment and control periods, thereby confusing
the results. In our study, 3/5 of our anephric patients
showed an increase in hematocrit, but when all five
were statistically analyzed and compared to the 24
with remnant kidneys, this change was not signifi-
cant. We conclude that this dosage of nandrolone
decanoate does not have a significant effect on the
anemia of anephric patients.
It is worth noting that as the studies of androgens
on uremic anemia have become more sophisticated
and controlled, the benefits, as measured by the
percent increase in hemoglobin or hematocrit,
regardless of the drug or dosage used, have fallen
progressively in both patients with remnant kidneys,
from a high of 33% [20] to a low in our study of 25%,
and in anephric patients from a high of 9% [30] to our
present insignificant improvement.
Adverse effects of this androgen treatment were
uncommon. Liver function tests remained normal
throughout the study, and significant virilizing
effects, priapism or changes in libido, did not occur.
The most common problem encountered was pain
Table 3. Comparison of triglyceride values before and after six
months of androgen therapy
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and/or hematoma at the site of injection, which
occurred in 7/37 patients. In the majority, this
occurred only during the first few injections, and
complaints decreased with time. There was a modest
increase in predialysis creatinine concentration and
muscle mass, as seen by the increase in average dry
weight, but this was not significant. One disturbing
effect of nandrolone decanoate was the increase in
serum triglyceride concentrations during therapy.
This agent does appear to aggravate the predisposi-
tion to hypertriglyceridemia seen in uremic patients
[39], and in view of the accelerated rate of athero-
sclerosis in dialysis patients [40] and the possible
atherogenic role of this lipid abnormality, this fact
should be considered prior to the onset of long-term
treatment with this anabolic agent. The type of
patient who is likely to develop this increased triglyc-
eride concentration was not fully evaluated in our
study, but it may be noteworthy that the anephric
patients had a slightly lower increase on average (32
vs. 53 mg/l00 ml) than the remnant kidney patient
group, but statistically this was not significant.
Certainly, the risk of hepatitis and sensitizing of
the patients secondary to regular transfusion is
reduced with the use of this drug. Our previous
policy, however, was no transfusions except in
emergency blood loss situations or rarely in cases of
severe symptomatic anemia (usually in the anephric
patient), so the modification of the above risk factor
was minimal in our dialysis population.
Expense must also be considered prior to wide-
spread use of this agent. A year's supply of the drug
at 200 mg weekly, i.m., costs $1,100 (Canadian) at
the time of the study.
Another parameter mitigating against indiscrimi-
nate use of the agent is the observed relation
between 1 7-alpha-alkalated agents and hepatocellu-
lar carcinomas [41, 42]. This has not been reported
with the l9-nortestosterone derivatives like nandro-
lone decanoate, but since the uremic population has
a higher than normal percentage of patients develop-
ing cancer [43] the observation cannot be ignored.
In conclusion, we have demonstrated that nandro-
lone decanoate is a safe and effective agent which
can be utilized for extended periods of time in the
treatment of uremic anemia. The side effects are few
and relatively minor, but in the long-term, the cost,
the accentuation of the lipid abnormality, coupled
with a limit to benefits achieved, including the lack of
effect in anephric patients, should promote a selec-
tive use of this agent to those who are likely to
respond. It seems appropriate that patients main-
tained on long-term dialysis programs because of
cytotoxic antibodies, age, or choice, who have rem-
nant kidneys and no sign of occult malignancy and
are bothered by symptomatic anemia, should be the
ones worthy of a trial of this medication.
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